MA59341A1 - Rifamycin analogs and antibody-drug conjugates thereof - Google Patents

Rifamycin analogs and antibody-drug conjugates thereof

Info

Publication number
MA59341A1
MA59341A1 MA59341A MA59341A MA59341A1 MA 59341 A1 MA59341 A1 MA 59341A1 MA 59341 A MA59341 A MA 59341A MA 59341 A MA59341 A MA 59341A MA 59341 A1 MA59341 A1 MA 59341A1
Authority
MA
Morocco
Prior art keywords
antibody
drug conjugates
growth
infections
aureus
Prior art date
Application number
MA59341A
Other languages
French (fr)
Inventor
Thomas Nittoli
Seungyong Sean Choi
Mrinmoy Saha
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA59341A1 publication Critical patent/MA59341A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés analogues de rifamycine, des intermédiaires et des précurseurs de ceux-ci, et des compositions pharmaceutiques capables d'inhiber la croissance bactérienne (par exemple, la croissance de s. Aureus) et de traiter des infections bactériennes (par exemple, des infections par s. Aureus). L'invention concerne en outre des conjugués anticorps-médicament de composés analogues de rifamycine et d'anticorps, par exemple, des anticorps spécifiques contre des cibles associées à une maladie infectieuse comme le récepteur de glycoprotéine membranaire (msr1), des acides téichoïques de paroi (wta) ou une protéine a, et des procédés d'utilisation de ceux-ci pour inhiber la croissance bactérienne et traiter des infections bactériennes.Disclosed herein are rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (eg, growth of S. Aureus) and treating bacterial infections (eg. example, S. Aureus infections). The invention further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific against targets associated with infectious disease such as the membrane glycoprotein receptor (msr1), cell wall teichoic acids (wta) or a protein, and methods of using the same to inhibit bacterial growth and treat bacterial infections.

MA59341A 2018-12-21 2021-07-28 Rifamycin analogs and antibody-drug conjugates thereof MA59341A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783506P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
MA59341A1 true MA59341A1 (en) 2023-05-31

Family

ID=83598749

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53783A MA53783A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof
MA59341A MA59341A1 (en) 2018-12-21 2021-07-28 Rifamycin analogs and antibody-drug conjugates thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53783A MA53783A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof

Country Status (1)

Country Link
MA (2) MA53783A1 (en)

Also Published As

Publication number Publication date
MA53783A1 (en) 2022-09-30

Similar Documents

Publication Publication Date Title
MX2021007524A (en) Rifamycin analogs and antibody-drug conjugates thereof.
MA47079A (en) AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER
MA52492B1 (en) RIP1 INHIBITORY COMPOUNDS, METHODS OF PREPARATION AND USE THEREOF
MX2021004707A (en) New anthelmintic compounds.
MA32104B1 (en) Oxime derivatives as inhibitors of hsp90
EA200701113A1 (en) Macrolides
JP2012504650A (en) Methods for regulating negative chemotaxis of immune cells
ES2171723T3 (en) 3,4-DIARIL-2-HYDROXI-2,5-DIHYDROFURANS AS COX-2 INHIBITORS PROPHARMS.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
WO2018155813A3 (en) Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium
MA53765A1 (en) Tubulysins and tubulysins-protein conjugates
MX2020007521A (en) Pi4kiiibeta inhibitors.
MA39926B1 (en) Cycloalkyl-linked diheterocycle derivatives
TNSN08537A1 (en) DRUG PRECURSORS OF THE PENEME TYPE
MA59341A1 (en) Rifamycin analogs and antibody-drug conjugates thereof
MX2022008901A (en) Protein-antiviral compound conjugates.
EA202191739A1 (en) ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM
MA46778B1 (en) Intranasal composition comprising betahistine
CR20190165A (en) Novel 5-substituted imidazolylmethyl derivatives
FR3081686B1 (en) FOOD COMPOSITION INCLUDING PHYCOCYANIN
MX2019013819A (en) Angiogenesis inhibitory oligopeptides and vascular function.
WO2020132603A3 (en) Salicyl-adenosinemonosulfamate analogs and uses thereof
WO2020099478A3 (en) Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
TW200616614A (en) A pharmaceutical composition for treating spinocerebellar ataxia
MA53135B1 (en) C-mannoside compounds useful for the treatment of urinary tract infections